Madurai News

Kaposi’s Sarcoma Market Is Expected To Grow During The Forecast Period (2019-2032), DelveInsight

 Breaking News
  • No posts were found

Kaposi’s Sarcoma Market Is Expected To Grow During The Forecast Period (2019-2032), DelveInsight

July 01
06:13 2022
Kaposi’s Sarcoma Market Is Expected To Grow During The Forecast Period (2019-2032), DelveInsight
Kaposi’s Sarcoma Market

DelveInsight’s “Kaposi’s Sarcoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Kaposi’s Sarcoma Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).


Kaposi’s Sarcoma: An Overview

Kaposi’s Sarcoma (KS) is a multicentric vascular tumor originating in the endothelial cells that line blood vessels and lymphatic vessels. KS is caused when tiny blood vessels develop below the surface of the skin, in the mouth, nose, eyes, or other parts of the body, such as the lymph nodes or lungs. Individuals with weak immune systems have a high risk of Kaposi’s Sarcoma. The lesions of Kaposi’s Sarcoma typically appear as painless purplish spots on the feet, legs, face, genital area, mouth, or lymph nodes. In severe Kaposi’s Sarcoma, lesions may develop in the lungs and digestive tract.


Download a sample copy of the Market Report @


Some of the key highlights of the Kaposi’s Sarcoma Market Report

  • Expected launch of the pipeline therapies such as sEphB4-HAS (Vasgene Therapeutics) and others shall fuel the growth of market during the forecast period (2022-2032).
  • As per Globocan (2020), the prevalence rate of Kaposi Sarcoma is 1.11 per 100,000 in the United States and its prevalence in the United Kingdom and Japan was found to be around 0.81/100,000 and 0.13/100,000, respectively.
  • As per the study titled “Risk of Kaposi’s Sarcoma after solid organ transplantation in the United States” conducted by Cahoon et al. (2018), KS incidence was 87% higher in men than women, over twofold greater in non-whites than whites, and two-fold higher in non‐US citizens than US citizens. KS incidence increased with age at transplant and decreased sharply with time since transplant, so that the highest incidence occurred within 1 year of transplant.
  • KS was a rare disease before the AIDS epidemic in the early 1980s, when the reported incidence of classic KS ranged from 0.01 per 100,000 person-years for the UK and 0.2 per 100,000 person-years for the USA. Incidence of KS is currently reported to be ~200 fold higher in recipients of solid-organ transplants (i.e., in iatrogenic KS) than in the general population.
  • At present, very few companies have initiated clinical trials that investigate new treatment options. Key players such as Vasgene Therapeutics (sEphB4-HAS), Bristol-Myers Squibb (Nivolumab and Ipilimumab), and several others are investigating their candidates for the management of Kaposi’s Sarcoma in the 7MM. In a nutshell, not many potential therapies are being investigated for the management of Kaposi’s sarcoma.


Kaposi’s Sarcoma Epidemiology Segmentation in the 7MM

  • Prevalent Cases
  • Age-specific Cases
  • Total Diagnosed Cases
  • Gender-specific Cases
  • Total Treated Cases


Kaposi’s Sarcoma Treatment Market

The main forms of treatment for Kaposi’s Sarcoma are Antiretroviral Therapy, Surgery, Photodynamic Therapy, Radiation Therapy, therapies using medications such as Chemotherapy, Topical medications, Targeted Therapy and Immunotherapy. Antiretroviral Therapy (ART) is the most important modes of treatment of Kaposi’s Sarcoma. This therapy is usually used before any other treatment to reduce the symptoms and treat the tumor. ART can be given alone or can also be given in combination with the chemotherapy depending on the symptoms and severity of the disease. However, rarely, ART can also cause some infections and worsen the Kaposi’s Sarcoma. This reaction is called immune reconstitution inflammatory syndrome (IRIS)


Explore more information about the treatment options @


Kaposi’s Sarcoma Therapies

 Therapies using the medications such as Chemotherapy, Topical Therapies and Immunotherapies are systemic therapies for destroying the cancer cells. Common ways to give systemic therapies include an intravenous (IV) tube placed into a vein using a needle or in a pill or capsule that is swallowed (orally). Targeted Therapies includes kinase inhibitors and immune-modulating drugs which blocks the growth and spread of cancer cells while limiting damage to healthy cells. Pomalidomide (Pomalyst) is approved to treat Kaposi’s Sarcoma if antiretroviral treatment has not been successful and adults with any Kaposi’s Sarcoma who are HIV-negative. Other drugs similar to Pomalidomide include lenalidomide (Revlimid) and thalidomide (Thalomid).


Kaposi’s Sarcoma Companies and Therapies:

  • Vasgene Therapeutics: sEphB4-HSA
  • Bristol-Myers Squibb: Nivolumab and Ipilimumab
  • And Many Others


Kaposi’s Sarcoma Market Dynamics

The dynamics of Kaposi’s Sarcoma market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also the expected launch of emerging therapies. Key players, such as Vasgene therapeutics and Bristol-Myers Squibb etc. are involved in developing drugs for Kaposi’s Sarcoma.


Download a sample copy of the Market Report @


Table of Content

1. Key Insights

2. Executive Summary of Kaposi’s Sarcoma

3. Competitive Intelligence Analysis for Kaposi’s Sarcoma

4. Kaposi’s Sarcoma: Market Overview at a Glance

5. Kaposi’s Sarcoma: Disease Background and Overview

6. Patient Journey

7. Kaposi’s Sarcoma Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Kaposi’s Sarcoma Unmet Needs

10. Key Endpoints of Kaposi’s Sarcoma Treatment

11. Kaposi’s Sarcoma Marketed Products

12. Kaposi’s Sarcoma Emerging Therapies

13. Kaposi’s Sarcoma: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Kaposi’s Sarcoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States

Recent Posts

Improve Work Tasks by Pairing INNOCN 27 Inch Monitor 27G1H with the Spacetop

Read Full Article